{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-25-000046","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.171522+00:00","generated_at":"2026-05-23T05:12:12.676533+00:00","sec_items":["2.02","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025","bullets":["5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.","No dose-limiting toxicities; preliminary RP2D set at 1.5x10^9 CAR NK cells Days 0,7,14 per 28-day cycle.","Longest ongoing response >8 months; 3 patients received bone marrow transplant after SENTI-202.","Q1 2025 preliminary: cash $33.8M, net loss $14.1M ($1.41/share); R&D $9.3M, G&A $7.1M.","SENTI-301A/SN301A HCC trial enrollment stopped due to dose-limiting toxicities; evaluating next steps."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-25-000046","json":"https://secwatch.observer/filing/0001854270-25-000046.json","markdown":"https://secwatch.observer/filing/0001854270-25-000046.md","text":"https://secwatch.observer/filing/0001854270-25-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/0001854270-25-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/snti-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:12:12.676533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}